Article Text

Download PDFPDF
Extended report
Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial
  1. Anna Tjärnlund1,
  2. Quan Tang1,
  3. Cecilia Wick1,
  4. Maryam Dastmalchi1,
  5. Herman Mann2,
  6. Jana Tomasová Studýnková2,
  7. Radka Chura3,
  8. Nicola J Gullick3,
  9. Rosaria Salerno3,
  10. Johan Rönnelid4,
  11. Helene Alexanderson5,
  12. Eva Lindroos1,
  13. Rohit Aggarwal6,
  14. Patrick Gordon3,
  15. Jiri Vencovsky2,
  16. Ingrid E Lundberg1
  1. 1 Rheumatology Unit, Department of Medicine, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden
  2. 2 Department of Rheumatology, Institute of Rheumatology, Prague, Czech Republic
  3. 3 Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK
  4. 4 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
  5. 5 Division of Physiotherapy, Department of Neurobiology, Karolinska Institutet and Physical Therapy Clinic, Karolinska University Hospital, Stockholm, Sweden
  6. 6 Division of Rheumatology and Clinical Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, USA
  1. Correspondence to Anna Tjärnlund, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden; anna.tjarnlund{at}ki.se

Footnotes

  • AT and QT contributed equally.

  • Handling editor Tore K Kvien

  • Contributors All authors were involved in drafting the article or revising it critically for important intellectual content. All authors approved the final version to be published and had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: AT, QT, CW, MD, HM, JTS, RC, NJG, RS, JR, HA, EL, RA, PG, JV, IEL. Acquisition of data: AT, QT, CW, MD, HM, JTS, RC, NJG, RS, JR, HA, EL, RA, PG, JV, IEL. Analysis and interpretation of data: AT, QT, CW, MD, HM, JTS, RC, NJG, RS, JR, HA, EL, RA, PG, JV, IEL. AT and QT contributed equally to this paper.

  • Funding This study was carried out as an investigator-initiated study funded by a grant from Bristol-Myers Squibb (BMS) and Börje Dahlin Foundation, Swedish Research Council GRANTK2014-52X-14045-14-3, Swedish Rheumatism Association, King Gustaf V 80-Year Foundation, and the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet. BMS provided the study drug. The presented work was initiated, conducted and performed independently of BMS.

  • Competing interests IEL: research grant and advisory board consultant for BMS, research grant from AstraZeneca, consultant for MedImmune, aTyr and IDERA. RA: research grant from BMS.

  • Patient consent Obtained.

  • Ethics approval The institutional review board at each study site.

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • AT and QT contributed equally.

  • Handling editor Tore K Kvien

  • Contributors All authors were involved in drafting the article or revising it critically for important intellectual content. All authors approved the final version to be published and had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: AT, QT, CW, MD, HM, JTS, RC, NJG, RS, JR, HA, EL, RA, PG, JV, IEL. Acquisition of data: AT, QT, CW, MD, HM, JTS, RC, NJG, RS, JR, HA, EL, RA, PG, JV, IEL. Analysis and interpretation of data: AT, QT, CW, MD, HM, JTS, RC, NJG, RS, JR, HA, EL, RA, PG, JV, IEL. AT and QT contributed equally to this paper.

  • Funding This study was carried out as an investigator-initiated study funded by a grant from Bristol-Myers Squibb (BMS) and Börje Dahlin Foundation, Swedish Research Council GRANTK2014-52X-14045-14-3, Swedish Rheumatism Association, King Gustaf V 80-Year Foundation, and the regional agreement on medical training and clinical research (ALF) between Stockholm County Council and Karolinska Institutet. BMS provided the study drug. The presented work was initiated, conducted and performed independently of BMS.

  • Competing interests IEL: research grant and advisory board consultant for BMS, research grant from AstraZeneca, consultant for MedImmune, aTyr and IDERA. RA: research grant from BMS.

  • Patient consent Obtained.

  • Ethics approval The institutional review board at each study site.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.